LENZ Therapeutics reports preliminary Q4 2025 results

LENZ Therapeutics, Inc., a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, has announced certain preliminary unaudited financial results for the fourth quarter ended December 31, 2025 and recent corporate updates. Approved by the FDA in August 2025, VIZZ is a once-daily aceclidine-based eye drop for the treatment of age-related presbyopia. The company reported the first commercial product sale of VIZZ in October 2025, with VIZZ net product revenue of approximately $1.6 million in the fourth quarter of 2025.

In making the announcement, the company advised that more than 20,000 prescriptions of VIZZ were filled through the fourth quarter, with what it said was “rapid uptake by prescribing eyecare professionals,” with over 6,500 unique prescribing ECPs and more than 55 percent prescribing multiple times. Launched in October 2025, the product was broadly available by mid-November. 

“We are proud of the strong execution delivered in our first quarter of launch, as the team established a solid foundation of awareness, confidence, and willingness to prescribe VIZZ across the eyecare professional community,” said Eef Schimmelpennink, president and CEO of LENZ Therapeutics. “More than 6,500 eyecare professionals have already written a prescription for VIZZ, the majority of whom prescribed multiple times, signaling early confidence in VIZZ as a convenient and effective alternative to reading glasses. “At the same time, over 20,000 prescriptions were filled during our first quarter of launch, exceeding our expectations and reinforcing the early momentum behind VIZZ,” he continued. “Building on this progress, and together with our campaign spokesperson Sarah Jessica Parker, we look forward to launching the VIZZ DTC campaign this quarter.”

This month, the company also announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. This agreement represents the fourth commercialization partnership for VIZZ outside the United States, the company noted.